<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04643795</url>
  </required_header>
  <id_info>
    <org_study_id>MGL-3196-10</org_study_id>
    <nct_id>NCT04643795</nct_id>
  </id_info>
  <brief_title>Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects</brief_title>
  <official_title>A Phase I, Open Label, Non-randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Madrigal Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Madrigal Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of&#xD;
      MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses&#xD;
      (QD x 6 days) in subjects with varying degrees of hepatic impairment (HI) compared to healthy&#xD;
      matched control subjects with normal hepatic function, including a subset of NASH subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetics - Cmax</measure>
    <time_frame>16 days</time_frame>
    <description>Cmax after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics - Tmax</measure>
    <time_frame>16 days</time_frame>
    <description>Tmax after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics - AUC (0-last)</measure>
    <time_frame>16 days</time_frame>
    <description>AUC (0-last) after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics - t1/2</measure>
    <time_frame>16 days</time_frame>
    <description>t1/2 after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on the incidence of adverse events</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>40 mg MGL-3196 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg MGL-3196 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg MGL-3196 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg MGL-3196 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple cohorts (normal, varying hepatic impairment, NASH non-cirrhosis, and NASH cirrhosis) evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGL-3196</intervention_name>
    <description>Once daily oral dose for 6 days</description>
    <arm_group_label>100 mg MGL-3196 Tablet</arm_group_label>
    <arm_group_label>40 mg MGL-3196 Tablet</arm_group_label>
    <arm_group_label>60 mg MGL-3196 Tablet</arm_group_label>
    <arm_group_label>80 mg MGL-3196 Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of understanding and willing and able to sign written informed consent&#xD;
&#xD;
          -  Male or female, between 18 and 85 years of age (inclusive)&#xD;
&#xD;
          -  BMI between 18 and 45 kg/m2 (inclusive)&#xD;
&#xD;
          -  In healthy subjects with normal hepatic function:&#xD;
&#xD;
               -  Considered by the Investigator to be healthy, based on medical and surgical&#xD;
                  history, physical examination including vital signs, 12-lead ECG, and laboratory&#xD;
                  test results&#xD;
&#xD;
               -  Match demographically with a subject in the hepatically impaired population&#xD;
                  according to gender, BMI (±20%), and age (±10 years)&#xD;
&#xD;
          -  In subjects with hepatic impairment:&#xD;
&#xD;
               -  Considered by the Investigator to be clinically stable with respect to underlying&#xD;
                  HI, based on medical and surgical history, physical examination including vital&#xD;
                  signs, 12-lead ECG, and laboratory test results&#xD;
&#xD;
          -  In subjects with NASH:&#xD;
&#xD;
               -  Confirmed diagnosis of NASH suggested by historical data, which include a&#xD;
                  previous liver biopsy within the last 5 years prior to randomization with&#xD;
                  evidence of NASH.&#xD;
&#xD;
               -  BMI ≥18 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any clinically significant concomitant disease or condition (including treatment for&#xD;
             such conditions) that, in the opinion of the Investigator, could either interfere with&#xD;
             the study drug, pose an unacceptable risk to the subject, or compromise interpretation&#xD;
             of study data&#xD;
&#xD;
          -  Gilbert's syndrome&#xD;
&#xD;
          -  Pre-existing condition interfering with normal gastrointestinal anatomy or motility,&#xD;
             hepatic and/or renal function that could interfere with the absorption, metabolism,&#xD;
             and/or excretion of study drug&#xD;
&#xD;
          -  eGFR &lt;60 mL/min/1.73 m2 based on Modification of Diet in Renal Disease (MDRD) equation&#xD;
&#xD;
          -  Received an investigational drug or device from another study within 30 days (or 5&#xD;
             half-lives, whichever is longer) prior to study drug administration&#xD;
&#xD;
          -  In healthy subjects with normal hepatic function:&#xD;
&#xD;
               -  Systolic blood pressure outside the range of 90 to 150 mmHg, diastolic blood&#xD;
                  pressure outside the range of 40 to 95 mmHg or heart rate outside the range of 40&#xD;
                  to 100 beats per minute (bpm)&#xD;
&#xD;
               -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14&#xD;
                  drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5&#xD;
                  ounces of hard liquor) within 6 months prior to screening&#xD;
&#xD;
          -  In subjects with hepatic impairment:&#xD;
&#xD;
               -  Any non-hepatic acute or chronic condition (including, but not limited to, poorly&#xD;
                  controlled diabetes and encephalopathy Grade ≥3) that, in the opinion of the&#xD;
                  Investigator, would limit the subject's ability to complete and/or participate in&#xD;
                  the study&#xD;
&#xD;
               -  Acute exacerbation of HI or unstable hepatic function, as determined by the&#xD;
                  Investigator, 30 days prior to study drug administration&#xD;
&#xD;
               -  Has had a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure&#xD;
                  performed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Edward Chiang</last_name>
    <phone>267-824-2827</phone>
    <email>ed@madrigalpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Madrigal Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madrigal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madrigal Research Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madrigal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Madrigal Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madrigal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

